Premarin Cream 0,625 mg Vaginal cream
PDF Leaflet Revision Date: 28 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of postmenopausal vulvovaginitis and atrophic vaginitis.
Dosage (summary)
0.5 to 2 grams daily, intravaginally; cyclic administration recommended.
Special Populations
- Elderly
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may decrease breast milk quality.
Key Drug Interactions
- CYP3A4 inducers/inhibitors may affect estrogen metabolism
Contraindications
- Hypersensitivity to estrogens
- Pregnancy
- Undiagnosed abnormal genital bleeding
- History of breast cancer
- Active thromboembolic disease
- Liver dysfunction
Common side effects
- Vaginitis
- Breast tenderness
- Dizziness
- Nausea
Counselling Points
- Use cyclically and for short-term only.
- Perform regular breast examinations.
- Report any unusual bleeding or mood changes.
Serious warnings
- Increased risk of stroke and DVT
- Potential for breast and endometrial cancer
- Monitor for mood changes and depression
Important Disclaimer
The Premarin Cream 0,625 mg Vaginal cream professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
